Biodesix, Inc. (BDSX)
BDSXNASDAQ-GMMedical Specialities
$10.50
+0.4800 (+4.79%) today
Regular session, Nov 11, 9:53 AM ET
- Market cap
- $116.43m
- P/E
- –
- EPS, last 4 quarters
- $-2.76
- Dividend yield
- –
- Day range
- $9.67 to $10.66
- 52-week range
- $5.26 to $31.97
- Average volume
- 145.0k
- Previous close
- $10.02
Analysts
5 coveringBuy5 buy, 0 hold, 0 sell
Targets a year out average $32.60, +210.5% from here
Earnings
next estimate $-0.7000Next report
Dec 2025
+53.3%
Mar 2026
+35.7%
Jun 2026
+17.4%
Sep 2026
-1.4%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | $21.77m | $28.75m | $25.55m | $26.86m |
| Gross profit | $17.66m | $23.88m | $21.35m | $22.04m |
| Operating income | -$7.05m | -$1.97m | -$6.20m | -$5.39m |
| Net income | -$8.72m | -$3.98m | -$7.79m | -$7.27m |
Last four quarters: revenue $102.94m, margin -27.0%, free cash flow -$20.24m
News
8 latest- Biodesix (BDSX) Q3 2026 Earnings Call TranscriptThe Motley Fool · 5 days ago
- Champions Oncology vs. Biodesix: Which Oncology Stock Is a Better Buy?Zacks · 5 days ago
- Biodesix, Inc. Reports Third Quarter 2026 Financial Results and Revises Full-Year Revenue Guidance to $101 million to $103 millionFintel · 5 days ago
- What Biodesix (BDSX) Said on Its Q3 Earnings CallMarketBeat · 6 days ago
- Biodesix, Inc. (BDSX) Reports Q3 Loss, Lags Revenue EstimatesZacks · 6 days ago
- Sera Prognostics, Inc. (SERA) Reports Q3 Loss, Lags Revenue EstimatesZacks · 7 days ago
- All You Need to Know About Biodesix (BDSX) Rating Upgrade to BuyZacks · Oct 29, 2026
- Will Biodesix, Inc. (BDSX) Report Negative Earnings Next Week? What You Should KnowZacks · Oct 29, 2026
The company
Biodesix is a leading diagnostic solutions company, driven to improve clinical care and outcomes for patients. Biodesix Diagnostic Tests, marketed as Nodify Lung Nodule Risk Assessment and IQLung Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable the world's leading biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics.
- Sector
- Health Care
- Industry
- Medical Specialities
- Exchange
- NASDAQ-GM
- Region
- North America
- Website
- biodesix.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.